Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

Celltrion, a major South Korean biopharmaceutical firm, said on Tuesday its two new bio-similars for bone disease treatment ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, ...

Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

South Korean biopharmaceutical giant Celltrion announced on Tuesday that its two new biosimilars for bone disease treatment have received approval from the United States Food and Drug Administration ...

SEOUL -- Forty-one ferry sailings and four flights were canceled nationwide Tuesday, anti-disaster authorities said, amid ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

South Korean stocks fell for the third consecutive session Tuesday, as US President Donald Trump's sweeping tariff scheme ...

Activist shareholders have been rarely visible ahead of the shareholders' meetings of listed companies later this month, a ...

Teens often spend hours daily watching videos online, but parents should consider how the content affects their well-being ...

Korean stocks opened slightly higher Tuesday, despite U.S. President Donald Trump's planned imposition of tariffs on Canadian ...